Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
Oliva S, Genuardi E, Paris L, D'Agostino M, Rogers J, Rota-Scalabrini D, Jacob AP, Patriarca F, Luppi M, Bertazzoni P, Velluti C, Capra A, Saraci E, Rossi M, Allegra A, Mina R, Gentile M, Kirsch IR, Belotti A, Cavo M, Bruno B, Musto P, Boccadoro M, Zamagni E, Gay F.
Oliva S, et al. Among authors: rossi m.
EClinicalMedicine. 2023 Jun 9;60:102016. doi: 10.1016/j.eclinm.2023.102016. eCollection 2023 Jun.
EClinicalMedicine. 2023.
PMID: 37396800
Free PMC article.